All News
Filter News
Found 5,698 articles
-
Antiaging Products And Services Market Is Estimated To Reach USD 41.23 Billion Growth By 2029 With Upcoming Trends, Revenue, Size, Share, Growth And Prominent Players
7/6/2022
Data Bridge Market Research Published Latest Global Antiaging Products and Services Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast.
-
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer's, Acer's vEDS program hits Phase III and BridgeBio's primary hyperoxaluria type 1 program progresses.
-
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
7/5/2022
Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services and former Governor of Wisconsin, to its Board of Directors.
-
Dementia Associated with Alzimer’s Disease Market: Growing Geriatric Population and Unmet Clinical Needs in Alzheimer’s Patients are Projected to Boost the Market
7/5/2022
Wilmington, Delaware, United States, Transparency Market Research Inc.: Transparency Market Research has published a new report titled, “Dementia Associated with Alzheimer’s Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.
-
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
7/4/2022
RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 4 to its Registration Statement on Form 20‑F with the U.S. Securities and Exchange Commission.
-
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
7/4/2022
RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced that the U.S. Food and Drug Administration has declined to issue an Emergency Use Authorization for aviptadil for a subgroup of patients that, in addition to aviptadil, also received remdesivir and continued to progress.
-
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
6/30/2022
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced interim data from the Company’s ongoing Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.
-
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
6/30/2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2022.
-
Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
6/30/2022
Aimmune Therapeutics, Inc., will present new data on PALFORZIA® [Peanut Allergen (Arachis hypogaea) Power-dnfp] at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Prague, Czech Republic on July 1-3, 2022.
-
Significant Growth Foreseen by Oxytocin Market During 2020 - 2030
6/30/2022
Wilmington, Delaware, United States: Industry interest in the neuropeptide hormone oxytocin has surged on the back of the profound role it has in human evolution.
-
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
6/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.
-
MindMed, Scripps Research, Cingulate Therapeutics and the University of Pennsylvania discuss innovative treatments on the horizon for the treatment of anxiety disorder.
-
Cell MedX Corp: Letter to Shareholders from Mr. Dwayne Yaretz, CEO
6/27/2022
Having recently accepted the positions of CEO and Director of Cell MedX, I wanted to introduce myself to you, highlight the Company's most recent accomplishments and our vision for the future.
-
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
6/24/2022
Mirum Pharmaceuticals, Inc. presented data at the International Liver Congress™ of The European Association for the Study of the Liver in London, United Kingdom.
-
Systemic Scleroderma Treatment Market: Competitive Landscape Analysis with Forecast by 2031
6/24/2022
Wilmington, Delaware, United States: An autoimmune disorder that affects the skin and internal organs is called systemic scleroderma.
-
First BPH Treatment Procedures Performed in Canada with Minimally Invasive iTind Device
6/23/2022
Olympus, a global technology leader in designing and delivering innovative medical technology solutions, announced today the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind™ procedure.
-
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
6/23/2022
VistaGen Therapeutics, Inc. (Nasdaq: VTGN), today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.
-
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
6/22/2022
Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).
-
Mesotherapy Market Segmentation and Forecast Analysis up to 2030
6/22/2022
Wilmington, Delaware, United States: Mesotherapy is a technique that is used to inject vitamins, enzymes, hormones, and plant extracts to rejuvenate and tighten skin as well as remove excess fat.
-
Acer Therapeutics and Relief Therapeutics announced the FDA has denied their NDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.